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Background/aim: The present study proposes to investigate the effect of neuropeptide–S (NPS) on cognitive functions and depressionlike behavior of MPTP-induced experimental model of Parkinson’s disease (PD).
Materials and methods: Three-month-old C57BL/6 mice were randomly divided into three groups as; Control, Methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) and MPTP + NPS 0.1 nmol (received intraperitoneal injection of MPTP and intracerebroventricular
injection of NPS, 0.1 nmol for seven days). The radial arm maze and pole tests were carried out, and the levels of tyrosine hydroxylase
(TH) were determined using western blotting. A mass spectrometer was used to measure the levels of dopamine, glutamic acid, and
glutamine.
Results: The T-turn and time to descend enhanced in MPTP group, while these parameters were decreased by NPS treatment. In
the MPTP group, the number of working memory errors (WME) and reference memory errors (RME) increased, whereas NPS
administration decreased both parameters. Sucrose preference decreased in the MPTP group while increasing in the NPS group. MPTP
injection significantly reduced dopamine, glutamic acid, and glutamine levels. NPS treatment restored the MPTP-induced reduction in
glutamine and glutamic acid levels.
Conclusion: NPS may be involved in the future treatment of cognitive impairments and depression-like behaviors in PD.
Key words: Parkinson’s disease, neuropeptide-S, cognition, depression-like behavior

1. Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s disease
(AD), and it is distinguished by classic cardinal motor
symptoms such as tremor, rigidity, and bradykinesia [1].
PD affects about 1% of people over the age of 60 [2].
Nonmotor symptoms of PD include depression, anxiety,
emotional and cognitive disabilities [3]. Dementia,
working memory, and learning deficits are examples of
cognitive dysfunctions [4]. In the early stages of PD, a
mean of 26.7% (range, 18.9%–38.2%) of patients have mild
cognitive impairment and 20 years after the diagnosis of
PD, 80% of these patients have dementia [5,6]. Depression,
which is considered a risk factor for cognitive dysfunction
in Parkinson’s disease, has a clinical significance of
approximately 40% in patients with early PD [7].
In PD, neurodegeneration is observed in the
hippocampus, entorhinal and prefrontal cortex, as well

as substantia nigra (SN) [8]. Changes in neurotransmitter
systems such as gamma-aminobutyric acid (GABA) and
glutamate have been linked to the symptoms (cognitive
impairment and depression) occurred in PD [9–11].
The
neurotoxin
methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP), which selectively damages
dopaminergic cells in the substantia nigra pars compacta
(SNpc), is widely used to induce PD models in mice and
rats [12]. In a previous study, it was observed that MPTP
causes impairments in associative memory and elements
of affective behavior [13]. MPTP also has an impact on
the glutaminergic system and the other neurotransmitter
systems [14].
Neuropeptide-S (NPS) is a 20 amino acids peptide
neurotransmitter present in the central nervous system
(CNS) of vertebrates such as primates, rodents, birds, and
amphibians [15–17]. NPS precursor protein has a similar
sequence with other sequences including Neuromedin
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U (NMU) and Neuromedin S (NMS) [18]. The NPS
precursor mRNA and Neuropeptide-S receptor (NPSR)
mRNA are highly expressed in locus coeruleus (LC),
lateral parabrachial nucleus, hypothalamus, thalamus,
cortex, and amygdala [15,17]. NPSR couples to Gs and
Gq proteins and potently increases intracellular calcium
levels and cyclic adenosine monophosphate (cAMP)
accumulation [15,19]. As a result, this receptor may have
an excitatory effect [20].
NPS has an anxiolytic-like effect and is critical in
controlling arousal which is expressed in a neuronal cluster
of cells in the LC [15]. Furthermore, NPS administration
elevates locomotor activity while decreasing paradoxical
(REM) sleep, slow-wave sleep and anxiety-related
behaviors [15] as well as food consumption and fear [21–
23].
NPS contributes to learning, spatial and contextual
memories by mediating glutamatergic neurotransmission
enhancement [24]. Zhao et al. found that NPS treatment
reversed cognitive deficits in a mouse model of AD by
upregulating the levels of postsynaptic density protein 95
(PSD95) and synapsin 1 in hippocampal CA1 neurons
[25].
To our knowledge, no research has been conducted
into the impact of NPS on cognitive disorders and
depression in PD. Therefore, the aim of this study was
to examine into the impact of NPS administration on
working memory and depression-like behaviors in MPTP
induced Parkinsonian mice. The second goal of our study
was to investigate and explain the function of glutamate,
glutamine, and dopamine in the impairment of working
memory in PD.
2. Materials and methods
2.1. Animals
In this study, three-month-old male C57Bl/6 mice
(25–30 g) were used. The animals were purchased from
the Akdeniz University Research Unit and were kept
in a standard laboratory setting with a temperature of
22 ± 2 °C and a 12-h light-dark cycle. They were given
unlimited amounts of food and water. The current study’s
experimental protocols were specifically approved by

icv
cannulation

injection of
MPTP/saline

the Institutional Animal Care and Use Committee at
Akdeniz University Medical School in Antalya, Turkey
(B.30.2.AKD.0.05.07.00/103).
2.2. Experimental design
The central NPS injection was applied through
intracerebroventricular
(icv)
cannula
implanted
chronically. Mice were randomly divided into three groups:
(i) Control group (received intraperitoneal (i.p.)
injection of saline, 0.9% NaCl solution),
(ii) MPTP group (received intraperitoneal (i.p.)
injection of MPTP and intracerebroventricular (icv)
injection of saline),
(iii) MPTP-injected + NPS treated (received
intraperitoneal (i.p.) injection of MPTP and
intracerebroventricular (icv) injection of NPS, 0.1 nmol
for 7 days, dissolved in 0.9% NaCl solution).
To create the PD model, MPTP was administered
4 times (2 times every day for two days, 4 × 20 mg/kg
MPTP) (M0896, Sigma, St. Louis, MO), and the control
group received saline with a 12-h interinjection period for
two days [26].
Mice were habituated to the laboratory and implanted
with a cannula in the lateral ventricle. After recovery period,
MPTP was administrated for two days and chronic NPS
injection (0.1 nmol) was applied for seven days. The radial
arm maze test was carried out for four days. At the end
of the NPS injection, the pole test and sucrose preference
test were performed on day 0. Animals were euthanized
and brain samples were collected for biochemical analysis.
Figure 1 showed details of the experimental procedure.
2.3. Icv cannulation
For the icv injections, the cannula was inserted into the right
lateral ventricle (–0.5 mm AP; 1,4 mm ML; 4 mm DV from
the bregma). It was fixed by cement and a dummy cannula
was placed into the guide cannula to prevent material
from entering. To verify that the cannula was located in
the correct coordinates, 150 ng human angiotensin-II was
administered by icv injection and allowed to access the
water. The amount of water consumed by the mice was
recorded [27]. Animals that did not consume water within
120 s were eliminated from experimental procotols.

habituation

Pole test
SPT

RAM test

Time (day)

Mass
spectrometry
&
Western blot

End point of experiment

-10

-9

recovery

-8

-7

-6

-5

-4

-3

-2

-1

0

Chronic NPS administration
(0.1 nmol)

Figure 1. Experimental design. RAM: Radial arm maze, SPT: Sucrose preference test, NPS: Neuropeptide-S.
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2.4. Behavioral test
2.4.1. Pole test
We performed the pole test on the seventh day after the last
MPTP injection to assess bradykinesia in the experimental
groups. Mice were placed on the top of a pole (diameter
8 mm, height 50 cm, with a rough surface) and allowed
to freely explore the pole before falling to the ground
(pretrial). After the animals were habituated to the test
system, the time it took the mice to completely turn down
(T-turn) and descend to the floor (time to descend) was
recorded (real trial) [28].
2.4.2. Radial arm maze (RAM)
To measure spatial learning and memory, the radial
arm maze (RAM) task was used in mice. The RAM tool
consisted of eight arms which have a food region at the end
of the arm. The numerous visual objects were fixed on the
wall of the maze to orientate itself. Mice were familiarized
by exploring the maze for 5 min per day for 3 days. On
the first day of habituation, mice were allowed to access
food (5 mg chocolate pellet for mice) from all arms before
being gradually restrained. Following habituation, each
trial was applied twice per day for 4 days. Arms 2, 3, 5,
and 7 were consistently baited with one food pellet during
each trial, whereas arms 1, 4, 6, and 8 were never baited
with food. Each animal was placed in the center of the
maze during each trial and testing day, and the working
and reference memory tasks were assessed [29]. The maze
was thoroughly cleaned and dried before each trial with
70% ethanol.
Three parameters were measured by a video tracking
system (Noldus EthoVision XT) in RAM; (i) the number
of reference memory errors (RME) (visits to unbaited
arms), (ii) the number of working memory errors (WME)
(visits to arms already visited in the same trial), and (iii)
the accuracy index (number of first entries into the baited
arms/total entries into all arms). Reference memory
is associated with long-term memory for information
that stays consistent through repeated trials (memory
for the positions of unbaited arms), while working
memory is correlated with short-time memory, in which
the information to be recalled changes with each trial
(memory for the positions of arms that had already been
visited in each trial).
2.4.3. Sucrose preference test (SPT)
Mice were given access to both water and a sucrose
solution and their preference for the sucrose solution was
quantified [30]. Briefly, the mice were exposed to a 1%
sucrose solution for 24 h. After habituation, the water and
sucrose bottles were then reintroduced to the mice for 24
h. Before and after the test, the bottles were weighed. The
total drinking was calculated as the sum of the water and
sucrose bottle consumptions. The sucrose preference was
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expressed as a percentage of total liquid consumption of
sucrose.
After the behavioral tests were completed on the
seventh day, the mice were sacrificed, and hippocampal
samples were collected for mass spectrometry and SN
tissues were taken for western blot analysis.
2.5. Protein measurements
A modified Bradford assay with Coomassie Plus reagent
was used to determine protein concentration at 595 nm
(Pierce Chemical Company) [31].
2.6. Western blot analysis
Proteins were extracted from SN tissues with lysis buffer
(0.1 M Tris at pH 7.4, 100 × Na-orthovanadate, pH 7.4)
supplemented with a protease inhibitor cocktail (P2714;
Sigma-Aldrich). The same amount of proteins from each
sample were separated on a 10% SDS-PAGE gel, transferred
to a nitrocellulose membrane (HATF00010; Millipore) at
4 °C overnight blotting, and hybridized with the primary
antibodies tyrosine hydroxylase (TH) (1:1000 dilution;
AB113, Abcam, Cambridge, MA, USA) and β-actin
(1:1000 dilution; ab16039, Abcam, Cambridge, MA, USA).
The membranes were then incubated for 1 h at room
temperature with horseradish peroxidase-conjugated
secondary antibodies. According to the manufacturer’s
instructions, an ECL system (RPN2232; Amersham
Biosciences, Buckinghamshire, United Kingdom) was
used to detect antibody-bound proteins, which were then
analyzed using ImageJ, 1.37v software.
2.7. Quantification of dopamine, glutamine and glutamic
acid
2.7.1. Sample preparation
The hippocampal tissues were homogenized in a 20-fold
volume of a formic acid solution (0.1 M). Homogenates
were centrifuged at 18,000 × g for 20 min at 4 °C. The
supernatants were collected and kept at – 80 °C until
analysis.
2.7.2. Mass spectrometry
The dopamine, glutamine, and glutamic acid standards
were provided by Sigma-Aldrich (St. Louis, MO, USA). As
previously described, a ultra-fast liquid chromatography
(UFLC) combined with mass spectrometry (MS/MS,
LCMS-8040, Shimadzu Corporation, Japan) was used
[32]. Gradient elution with a flow rate of 0.4 mL/min was
used to detect dopamine, glutamine, and glutamic acid.
Mobile phase solvent A was water containing 0.1% formic
acid and 1% acetonitrile, while solvent B was acetonitrile
containing 0.1% formic acid. In positive electrospray
ionization (ESI), multiple reaction monitoring (MRM)
transitions and responses were automatically optimized
for dopamine, glutamine, and glutamic acid. Dopamine,
glutamine, and glutamic acid responses were optimized
to a linear calibration range of 50 to 1000 ng/mL and a
sample analysis time of 4 min [33].
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2.8. Statistical analysis
The data was presented as the mean ± SEM, and statistical
analyses were carried out with the GraphPad Prism
software. For the suit with normal distribution, the
differences in the pole test, SPT, and mass spectrometry
were analyzed using ANOVA followed by Tukey’s posthoc
test; the differences in the Western blot were analyzed using
Kruskal–Wallis followed by the Mann–Whitney U test.
Two-way ANOVA (repeated measure) was used to analyze
the RME and WME in RAM, followed by Bonferroni
correction. The corresponding p values are shown in
the figure legends. The asterisk sign denotes statistical
significance between the control and MPTP groups, while
the # pound sign indicates statistical significance between
the MPTP and MPTP plus NPS groups.
3. Results
3.1. Pole test
Motor deficits were expressed using the pole test to
investigate the effect of NPS on the behavioral deficits
caused by MPTP administration. MPTP administration
induced an increase in the descending time and T-turn
of mice (p < 0.0001), which was restored by NPS
treatment (p < 0.0001). These findings suggest that NPS
has neuroprotective properties against MPTP-induced
behavioral deficits (Figure 2).
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3.2. Radial arm maze
Figure 3 illustrates reference and working memory errors
in different groups. Our observation reveals that the NPS
treatment leads in a significant decline in RME when
compared to the MPTP group. Altogether, when mice
were injected with MPTP, the number of WME increased
significantly when compared to controls. As a result of the
RAM behavior data analysis, NPS treatment has a positive
effect on the MPTP-induced PD model in learning and
memory.
3.3. Sucrose preference test
When compared to control animals in the SPT, the
MPTP group showed a decreased preference for sucrose
(p < 0.05). This effect was significantly reversed by NPS
treatment (p < 0.01) (Figure 4).
3.4. Western blot
On day 7, there was an increase in the expression of tyrosine
hydroxylase (TH) in the SN tissues. MPTP administration
caused dopaminergic neuronal death in the SN, but NPS
administration suppressed it (p < 0.05) (Figure 5).
3.5. Quantitative mass spectrometric measurements
dopamine, glutamine and glutamic acid
After mice were sacrificed and hippocampal samples were
obtained, mass spectrometry was used to determine the
levels of dopamine, glutamine, and glutamic acid. MPTP
caused a remarkable decrease in the levels of dopamine,

Figure 2. Determination of bradykinesia by pole test. (a) T-turn (s). (b)
Time to descend (s). Data are means ± SEM. Statistical analyses are one-way
ANOVA followed by Tukey’s multiple comparison test against the indicated
group (n = 10).
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Figure 3. The effect of chronic NPS treatment on memory in radial arm maze task. (a) RME (b) WME. Data are represented as mean ±
standard error of the mean. * p < 0.05 vs. Control; ** p < 0.01 vs. Control; *** p < 0.001 vs. Control; # p < 0.05 vs. MPTP group; ###p <
0.001 vs. MPTP group (n = 10).
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Figure 4. The sucrose preference assay. Values represent means
± SEM (n = 6).

glutamine and glutamic acid in hippocampal tissues. When
compared to the MPTP animals, NPS treatment resulted
in a significant increase in glutamine and glutamic acid
levels, but not in dopamine level (Figure 6).
4. Discussion
As an important endogenous neuropeptide, NPS has been
indicated to play an effective role in working memory and
depression in a mouse model of MPTP-induced PD. The
current study demonstrated that NPS treatment improved
the working memory and reduced the depression-like
behaviors as measured by RAM and SPT, respectively.
Western blot and mass spectrometry techniques were used
to support these findings.
Although a variety of neurotoxins, including
6-hydroxydopamine (6-OHDA), paraquat, maneb, and
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rotenone, are used to mimic the pathological features of
PD, MPTP is one of the best models that is most similar to
human PD [34]. MPTP is oxidized to MPP+, which alters
the permeability of the mitochondrial inner membrane,
inhibits complex I of the mitochondrial electron transport
chain, and causes ATP depletion in dopaminergic neurons
[35]. The C57BL/6 mouse strain is more vulnerable
to systemic MPTP than other mouse strains [36]. We
preferred to inject MPTP (i.p.) at a dose of 4 × 20 mg/kg
every 12 h for 2 days [26]. The primary reason for selecting
this dose and method of administration is to reduce the
mortality of mice.
Bradykinesia, which is the common symptom and
indicator of motor activity in PD, was assessed using a pole
test in the current study. According to the findings, MPTP
injection increased the descending time and T-turn.
However, 0.1 nmol NPS administered centrally has been
shown to reduce the severity of bradykinesia. Okamura
and colleagues discovered that NPS (icv) treatment
reduced inactivity in a dose-dependent manner [37].
Furthermore, in our recent study, we have reported that
administration of NPS restored the locomotor activity in
6-OHDA induced PD model of rats [33]. These findings
explain why central NPS treatment reverses behavioral
deficits.
The marker in the identification of dopaminergic
neurons is TH, the rate-limiting enzyme in dopamine
synthesis, which is known to be diminished in PD and in
PD animal models [38, 39]. In our study, in the SN, TH
expression levels were noticeably reduced in the MPTP
group relative to the control group while NPS treatment
attenuated the decrease in TH.
In a study conducted by Zhu et al., the levels of DA
and 3,4-dihydroxyphenylacetic acid (DOPAC) in the
hippocampal tissues were found to be significantly lower
in the MPTP-intoxicated PD group [40]. In line with Zhu
et al.’s findings, in our study, the levels of dopamine in the
hippocampal tissue reduced with MPTP injection; whereas,
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Figure 5. The expression of TH. All data are shown as the means ± standard error mean (n =
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Figure 6. The effect of central NPS treatments on the dopamine, glutamine and glutamic acid
concentrations in hippocampal tissues. (a) Dopamine (n = 6), (b) Glutamic acid (n = 6), (c) Glutamine
(n = 5). One-way ANOVA followed by Tukey posthoc was used to test the effect of NPS treatments.

chronic NPS administration caused an increase but did not
reach a significant level. MPTP administration increases
glutamate efflux in the brain and causes hyperactivity of
the glutamatergic system. When glutamate and glycine
bind to N-methyl-d-aspartate (NMDA) receptors, they
open the channel and cause calcium influx, resulting in
neuronal excitation. Therefore, MPTP administration
causes neuronal death by increasing glutamate release. In
chronic MPTP intoxication, glutamatergic transmission
shifts from hyper- to hypoactivity [10]. Although no

changes in glutamate and glutamine levels have been
observed in PD [5, 11], one study found that they differed
between PD and control patients [9]. In this study, the
MPTP administration caused a remarkable decrease in
glutamate and glutamine levels. The NPS induced increases
in glutamate and glutamine levels were observed but
only glutamine levels showed a significant improvement.
However, NPS-mediated augmentation of glutamatergic
neurotransmission in the amygdala was observed in two
previous studies [41, 42].
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According to our knowledge, SN is the most affected
region in PD. Dopaminergic projections are sent to the
hippocampus by the SN and the ventral tegmental area
(VTA) [43]. On the other hand, cognitive disorders such as
attention, spatial memory, and learning are observed in PD
patients and animal models [44]. The robust impairment
of habit learning and spatial working memory were
observed in the MPTP model of rats [45,46]. MPTP causes
dopaminergic neurodegeneration and neuroinflammation
in the hippocampus. Neuroinflammation, characterized by
microglial activation and cell loss in the hippocampus, leads
to cognitive dysfunction associated with dopaminergic
degeneration [47]. Cognitive deficits in MPTP-treated
mice were associated with decreased autophosphorylation
of calcium/calmodulin-dependent protein kinase II
(CAMKII) in the hippocampus [48]. RAM is commonly
used to determine cognitive function in rodents [49]. Our
RAM results revealed a significant difference in reference
memory errors on the third day between the control and the
MPTP group. While in the MPTP group, WME increased
significantly on the second, third, and fourth days. Previous
studies have shown that intranasal MPTP administration
led to significant working memory impairments [50, 51].
Thus, these memory deficits observed in PD patients are
largely the result of a learning deficit [52]. The underlying
mechanism of cognitive disorders is the alteration of
synaptic plasticity as a result of altered hippocampal LTP.
However, LTP is a cellular indicator of synaptic plasticity,
learning, and memory. LTP and LTD, two forms of synaptic
plasticity, are modulated by endogenous dopamine
[53]. Moreover, the decrease of NR2A/NR2B subunit
ratio in synaptic N-methyl-D-aspartic acid receptors
affects hippocampal LTP [54]. Working memory, which
is assessed by RAM, is impaired in PD, and this deficit
damages the synaptic integrity of the hippocampus [55].
However, disruptions in other neurotransmitter systems
beyond the dopamine underlie some non-motor symptoms
of PD [56]. Crabbe and colleagues have reported that the
levels of dopamine, serotonin and glutamine were altered
in experimental PD [14]. Similarly, our present findings
confirm that, when compared to control animals, MPTP
significantly decreased glutamate and glutamine levels.
On the third and fourth days, NPS treatment
significantly reduced RME. Besides, there was a statistically

significant difference in the number of WME between
MPTP and the MPTP + NPS 0.1 nmol groups on all days.
As a result, both parameters were found to be decreasing
with chronic NPS administration. NPS plays an important
role in the recall and consolidation of various types of
memory, which induces memory enhancement. Retention
of recognition memory was significantly prolonged by
NPS [23]. NPS also stimulates glutamatergic synaptic
neurotransmission [20]. Therefore, all of these findings
explain how NPS affects behavioral parameters.
The SPT is used to assess the depression-like behaviors
[30]. The depressive-like behavior in animal models of PD,
observed in the SPT, was correlated with a reduction in
striatal dopamine and hippocampal serotonin content.
In this way, the dopaminergic deficit may be linked to
this behavior [57, 58]. These noradrenergic, serotonergic
and dopaminergic changes in the striatal system lead
to depression-like behavior in PD [59]. In this study,
compared to controls, dopamine level was reduced
significantly in mice injected with MPTP. MPTP induced
reduction in the sucrose preference ratio was increased in
mice received 0.1 nmol of NPS treatment. Therefore, NPS
seems to be effective in antidepressant-like behaviors. To
regulate behavioral parameters, the NPS system interacts
with other neurotransmitter systems. The anatomical
distribution of the NPS in the brain determines this
interplay [37]. As a result, this study demonstrates that NPS
treatment affects cognitive impairments and depressionlike behaviors in the experimental mouse model of PD.
5. Conclusion
In conclusion, our findings show that NPS has a protective
effect in the MPTP-induced Parkinson’s disease mouse
model. Impairments of cognitive parameters and
behavioral deficits in Parkinsonian mice were recovered
by NPS treatment. However, more research is needed to
determine the protective mechanism involved in the effect
of NPS on cognitive dysfunction and depression in an
MPTP-induced mouse model of PD.
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